A biopharmaceutical company focused on developing and acquiring aesthetic medicines and therapeutic products. The company's lead product is EL-22, an engineered probiotic designed to address obesity by preserving muscle mass during weight loss treatments. PMGC Holdings also engages in medical scientific research and development activities and operates investment firms.